Results 161 to 170 of about 667,198 (303)

Small vesicles, big potential: A review of innovative exosome delivery and molecular mechanisms in preclinical myocardial infarction models

Animal Models and Experimental Medicine, EarlyView.
This narrative review discusses animal models of exosome‐based myocardial infarction treatments. Emerging techniques aim to improve exosome stability, targeting, and bioavailability for MI treatment as drug delivery vehicles and regenerative mediators that promote myocardial regeneration. Abstract Exosomes have emerged as promising therapeutic carriers,
Chayanisa Phutiyothin, Kovit Pattanapanyasat, Sarawut Kumphune   +2 more
wiley   +1 more source

Cytokine Pathways Driving Diverse Tissue Pathologies in Rheumatoid Arthritis

Arthritis &Rheumatology, EarlyView.
Rheumatoid arthritis (RA) is a complex systemic disorder characterized primarily by articular inflammation and destruction with associated functional loss and reduced quality of life. RA is also associated with extra‐articular disease, such as that of the lung, with potentially devastating clinical consequences. The critical importance of comorbidities,
Aurelie Najm, Lyn D. Ferguson, Iain B. McInnes   +2 more
wiley   +1 more source

Pulmonary Endothelium: A Driver and Therapeutic Target in Pulmonary Hypertension. [PDF]

JACC Basic Transl Sci
Kovacs-Kasa A, Annex BH.
europepmc   +1 more source

Long‐Term Outcomes of Reduced‐Intensity Conditioning Hematopoietic Stem Cell Transplantation for Patients With Systemic Sclerosis With Impaired Cardiac Function

Arthritis &Rheumatology, EarlyView.
Objective High‐intensity conditioning autologous hematopoietic stem cell transplantation (AHSCT) is standard of care for patients with advanced systemic sclerosis (SSc). The role of reduced‐intensity conditioning (RIC) before AHSCT in this population remains unclear.
Yonatan Lean, Carrie Richardson, Anthony J. Esposito, Katy Bedjeti, George E. Georges   +4 more
wiley   +1 more source

Selexipag for Pulmonary Hypertension, TAVI and more. [PDF]

Anatol J Cardiol
Erol Ç.
europepmc   +1 more source

Impact of Evolving Treatment Patterns on Interstitial Lung Disease Progression in Systemic Sclerosis Using the European Scleroderma Trials and Research Database

Arthritis &Rheumatology, EarlyView.
Objective The treatment landscape for systemic sclerosis‐associated interstitial lung disease (SSc‐ILD) has evolved with increasingly available immunosuppressive therapies (ISTs) and antifibrotic treatments. However, their real‐world use remains unclear.
Corrado Campochiaro, Marie‐Elise Truchetet, Madelon Vonk, Giacomo De Luca, Giovanna Cuomo, Lidia P. Ananieva, Eric Hachulla, Vanessa Smith, Ana Maria Gheorghiu, Radim Becvar, Patricia Carreira, Nicolas Hunzelmann, Daniel E. Furst, Vera Ortiz‐Santamaria, Francesco Del Galdo, Marco Matucci‐Cerinic, Anna‐Maria Hoffmann‐Vold, EUSTAR collaborators   +17 more
wiley   +1 more source

Predicting pulmonary hypertension in infants with bronchopulmonary dysplasia. [PDF]

J Perinatol
Foote HP, Sun M, Goldstein BA, Hill KD, Greenberg RG, Gentle SJ, Zimmerman KO, Kamaleswaran R, Tolia VN, Laughon MM, Jackson W, Hornik CP.   +11 more
europepmc   +1 more source

Impact of Early Antimalarial Adherence on Future Acute Care Utilization and Cost Among Patients With Rheumatoid Arthritis and Systemic Lupus Erythematosus: A Population‐Based Study

Arthritis &Rheumatology, EarlyView.
Objective To assess the association between early antimalarial adherence and future acute care utilization and cost in a population‐based cohort of incident rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE). Methods All patients with incident RA/SLE and new antimalarial use in British Columbia, Canada, between January 1997 and March 2022
Md Rashedul Hoque, Diane Lacaille, J. Antonio Aviña‐Zubieta, Mary A. De Vera, Yi Qian, Lawrence McCandless, John M. Esdaile, Hui Xie   +7 more
wiley   +1 more source

Phenotyping vasodilator responsiveness in idiopathic pulmonary arterial hypertension: any role for the cardiopulmonary exercise test?

ERJ Open Research
Gayathiri Sivasubramaniam, Andrea Baccelli, Gulam Haji, Francesco Lo Giudice, Clare Weaver, Luke Howard, Rachel Davies   +6 more
doaj   +1 more source

Efficacy and Safety of Guselkumab in Participants With Active Psoriatic Arthritis After Inadequate Response to One Prior Tumor Necrosis Factor Inhibitor: Week‐24 Results of a Phase 3, Randomized, Placebo‐Controlled Study

Arthritis &Rheumatology, EarlyView.
Objective To evaluate the efficacy and safety of guselkumab, an interleukin‐23p19 subunit inhibitor, in participants with active psoriatic arthritis (PsA) and inadequate response (inadequate efficacy and/or intolerance) to one prior tumor necrosis factor (TNF) inhibitor.
Alexis Ogdie, Joseph F. Merola, Philip J. Mease, Christopher T. Ritchlin, Jose U. Scher, Kimberly Parnell Lafferty, Daphne Chan, Soumya D. Chakravarty, Wayne Langholff, Yanli Wang, Jie Shao, Yevgeniy Krol, Alice B. Gottlieb   +12 more
wiley   +1 more source